Related Experiment Video
Updated: May 19, 2026
Conducting Respiratory Oscillometry in an Outpatient Setting
Published on: April 8, 2022
Bronchodilator use and the risk of arrhythmia in COPD: part 1: Saskatchewan cohort study
Machelle Wilchesky1, Pierre Ernst2, James M Brophy3
1Donald Berman Maimonides Geriatric Centre, McGill University, QC, Canada; Centre for Clinical Epidemiology, Jewish General Hospital-Lady Davis Research Institute, Montreal, QC, Canada.
Insights
New bronchodilator use, especially ipratropium and long-acting beta-agonists (LABAs), may increase cardiac arrhythmia risk in COPD patients. Further research is needed to confirm these findings, particularly for LABAs.
Area of Science:
- Cardiology
- Pulmonology
- Pharmacology
Background:
- Bronchodilators are primary treatments for Chronic Obstructive Pulmonary Disease (COPD).
- Existing research suggests a potential link between bronchodilator use and cardiac arrhythmias.
Purpose of the Study:
- To investigate the association between new bronchodilator use and the risk of cardiac arrhythmias in patients with COPD.
- To evaluate specific bronchodilator classes, including ipratropium, short-acting beta-agonists, long-acting beta-agonists (LABAs), and methylxanthines.
Main Methods:
- A cohort of 6,018 COPD patients aged 55+ was identified from Saskatchewan health databases (1990-1999).
- A nested case-control approach followed patients until 2003, analyzing hospital admissions or deaths from arrhythmia.
- Conditional logistic regression estimated the rate ratio (RR) of arrhythmia associated with new bronchodilator use, adjusting for disease severity and comorbidities.
Main Results:
- The study identified 469 arrhythmia cases (including 56 deaths) in the COPD cohort.
- New use of ipratropium showed an elevated arrhythmia risk (RR, 2.4; 95% CI, 1.4-4.0).
- New use of long-acting beta-agonists (LABAs) also indicated an increased risk (RR, 4.5; 95% CI, 1.4-14.4), though based on limited cases. Risks were not elevated for short-acting beta-agonists or methylxanthines.
Conclusions:
- New bronchodilator use, particularly ipratropium and LABAs, may be associated with a higher risk of cardiac arrhythmias in COPD patients.
- The findings suggest caution with ipratropium and LABAs in this population.
- Further validation in larger cohorts is recommended, especially for LABAs, due to the small number of cases observed.
Background:
Bronchodilators are first-line therapy for COPD. There is some evidence that they may increase the risk of cardiac arrhythmias.
Methods:
We used the computerized health-care databases of the Province of Saskatchewan, Canada, to identify a cohort of subjects with COPD, aged ≥ 55 years, between 1990 and 1999. The subjects were followed until December 2003 for a hospital admission for, or death from, arrhythmia. A nested case-control approach was used to match each arrhythmia case on age, sex, and calendar time to 20 control subjects selected from the corresponding cohort risk set. Conditional logistic regression was used to estimate the rate ratio (RR) of arrhythmia associated with new use of bronchodilators, adjusted for disease severity and comorbidity.
Results:
The cohort included 6,018 patients with COPD in whom 469 arrhythmia cases occurred, including 56 deaths, for an overall rate of 1.37 arrhythmias per 100 per year. The rate of arrhythmia was elevated with the new use of ipratropium (RR, 2.4; 95% CI, 1.4-4.0) and of long-acting β-agonists (LABAs) (RR, 4.5; 95% CI, 1.4-14.4). It was not elevated with new use of short-acting β-agonists (RR, 0.9; 95% CI, 0.5-1.6) or methylxanthines (RR, 1.6; 95% CI, 0.7-3.7).
Conclusions:
The new use of bronchodilators, particularly ipratropium and LABAs, may increase the risk of cardiac arrhythmias in patients with COPD. Although these results raise concerns regarding LABAs, they were based on few cases and require confirmation in larger cohorts.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
01:24Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:20COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:23Chronic Obstructive Pulmonary Disease I: Introduction
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...